Professor Dr. Matthias Liechti

The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing.  Taking place at the University Hospital Basel (UHB), this...

The COVID-19 coronavirus has prompted mass business closures, leading some economic forecasters to suggest 50 million jobs may be vulnerable to permanent layoffs, a scenario that may fuel the emergence of a mental health catastrophe. In a bid to address the arrival of a national health crisis, Mind...

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel. Exploring High-Dose LSD...